The partnership comes at a time when new Alzheimer's drugs are emphasizing the importance of MRI in patient management. The AI technology can extract quantitative measurements from brain scans, enhancing the diagnostic process and enabling quicker decision making. The collaboration aims to address staff shortages, lower care costs, increase diagnostic confidence, and facilitate personalized care plans.
Key takeaways:
- Royal Philips and icometrix have partnered to develop an AI-driven solution for acquiring, reading, and reporting the results of MRI brain scans to optimize diagnosis and treatment monitoring of neurological conditions including Alzheimer’s and multiple sclerosis (MS).
- The AI-powered quantitative reporting software from icometrix is integrated into Philips’ latest BlueSeal MR scanners and will also be deployed on Philips’ healthcare informatics platform.
- The introduction of new drugs that slow the progression of Alzheimer’s emphasizes the critical role of MRI in patient management. AI’s ability to extract quantitative measurements from brain scans enhances the diagnostic process, enabling quicker decision making and improved monitoring of disease progression.
- Philips’ latest BlueSeal MR scanners are delivered with standardized AI-based SmartExam planning and AI-accelerated SmartSpeed protocols to image ARIA quickly and easily. Philips unique Smart Reading software also allows end-to-end seamless integration of imaging protocols with the icometrix icobrain ARIA software to deliver fast, fully automated, quantitative outcomes for Alzheimer’s patients.